b
Thank You！
Your requirement has been sent, we will contact you quickly!
Sent Failed！
Try again!
Eplerenone, a novel selective aldosterone receptor antagonist, was approved for clinical use by the State Food and Drug Administration in 2002, is pure white or white crystal, antagonizes aldosterone action more strongly than spironolactone, and has very low affinity for androgen and progesterone receptors, has little adverse effects, and has definite efficacy in the treatment of hypertension, heart failure and myocardial infarction, Adverse effects were few and well tolerated, making spironolactone a good alternative.
CDMO
